Marianne De Backer, M.Sc., Ph.D., MBA

Marianne De Backer, M.Sc., Ph.D., MBA

President, Chief Executive Officer and DirectoratVir Biotechnology· In proxies 2023–2025

Pay in FY2025-15% from the year before · Vir Biotechnology stock -17.8% the same year

Marianne De Backer, M.Sc., Ph.D., MBA was paid $7.8M in FY2025 (Dec), down 15%. Vir Biotechnology stock fell 17.8% that year.

Pay$100 in the stock at the end of FY22 → $24
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 3 yr
    • President, Chief Executive Officer and Director2023 – Present · 3 yrStock in role -52%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?